Abstract
B-cell lymphomas represent a heterogeneous collection of more than twenty-five different malignancies. Classification is often challenging as primarily based upon, sometimes subjective, histopathological criteria and misdiagnosis can result in inappropriate treatment decisions. MicroRNAs (miRNAs) hold great promise as novel biomarkers (diagnostic, prognostic and predictive) of B-cell lymphoma in addition to being potential therapeutic targets. The most promising of these miRNAs more often than not play key regulatory roles in lymphopoiesis (development of lymphocytes) when under physiological conditions, and in the pathology of lymphoid malignancies when aberrantly expressed. In this review we consider the identity and functional role of miRNAs in the most common forms of B-cell lymphomas, their role in lymphopoiesis and their potential as biomarkers for these malignancies.
Keywords: Biomarker, blood, diffuse large B cell lymphoma, lymphoma, lymphomagenesis, microRNA.
MicroRNA
Title:Aberrant Expression of MicroRNAs in B-cell Lymphomas
Volume: 5 Issue: 2
Author(s): Carla Sole, Erika Larrea, Lorea Manterola, Ibai Goicoechea, María Armesto, María Arestin, María M. Caffarel, Angela M. Araujo, Marta Fernandez-Mercado, María Araiz and Charles H. Lawrie
Affiliation:
Keywords: Biomarker, blood, diffuse large B cell lymphoma, lymphoma, lymphomagenesis, microRNA.
Abstract: B-cell lymphomas represent a heterogeneous collection of more than twenty-five different malignancies. Classification is often challenging as primarily based upon, sometimes subjective, histopathological criteria and misdiagnosis can result in inappropriate treatment decisions. MicroRNAs (miRNAs) hold great promise as novel biomarkers (diagnostic, prognostic and predictive) of B-cell lymphoma in addition to being potential therapeutic targets. The most promising of these miRNAs more often than not play key regulatory roles in lymphopoiesis (development of lymphocytes) when under physiological conditions, and in the pathology of lymphoid malignancies when aberrantly expressed. In this review we consider the identity and functional role of miRNAs in the most common forms of B-cell lymphomas, their role in lymphopoiesis and their potential as biomarkers for these malignancies.
Export Options
About this article
Cite this article as:
Sole Carla, Larrea Erika, Manterola Lorea, Goicoechea Ibai, Armesto María, Arestin María, Caffarel M. María, Araujo M. Angela, Fernandez-Mercado Marta, Araiz María and Lawrie H. Charles, Aberrant Expression of MicroRNAs in B-cell Lymphomas, MicroRNA 2016; 5 (2) . https://dx.doi.org/10.2174/2211536605666160825150830
DOI https://dx.doi.org/10.2174/2211536605666160825150830 |
Print ISSN 2211-5366 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-5374 |
Call for Papers in Thematic Issues
Modulatory Roles of Non-coding RNAs in cancer therapy
This thematic issue aims to elucidate the most recent research on ncRNAs in CRCs and discuss the importance and difficulties that may arise in applying this tool on a regular clinical basis.read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
<i>In vitro</i> and <i>in vivo</i> Evaluation of 17-phenylpropylamine/phenoxyethylamine- 17-demethoxygeldanamycins as Potent Hsp90 Inhibitors
Medicinal Chemistry Targeting the SH2 Domain-Containing Inositol Phosphatase (SHIP) for Therapy
Current Enzyme Inhibition Polymer-Drug Nanoconjugate – An Innovative Nanomedicine: Challenges and Recent Advancements in Rational Formulation Design for Effective Delivery of Poorly Soluble Drugs
Pharmaceutical Nanotechnology Editorial (Thematic Issue: “Current Trend in Oncolytic Virus Therapy Against Cancers”)
Current Cancer Therapy Reviews Molecularly Guided Therapy of Neuroblastoma: A Review of Different Approaches
Current Pharmaceutical Design New N’-Arylidene-2-[(4-Nitrophenyl)Piperazın-1-yl]Acetohydrazide Derivatives: Synthesis and Anticancer Activity Investigation
Letters in Drug Design & Discovery Biologic Therapy in Immune Mediated Inflammatory Disease: Basic Science and Clinical Concepts
Current Drug Safety Plant Phenolic Compounds as Potential Lead Compounds in Functional Foods for Antiviral Drug Discovery
Current Organic Chemistry Lipoxygenase Inhibitors as Cancer Chemopreventives: Discovery, Recent Developments and Future Perspectives
Current Medicinal Chemistry Anti-Angiogenic Drugs and Biomarkers in Non-Small-Cell Lung Cancer: 'A Hard Days Night'
Current Pharmaceutical Design Channel-Like Functions of the 18-kDa Translocator Protein (TSPO): Regulation of Apoptosis and Steroidogenesis as Part of the Host-Defense Response
Current Pharmaceutical Design Radiolabeled Nucleosides for Predicting and Monitoring the Cancer Therapeutic Efficacy of Chemodrugs
Current Medicinal Chemistry The Potential Therapeutic Use of Stem Cells in Cartilage Repair
Current Stem Cell Research & Therapy Targeting Hypoxia-Inducible Factor-1 (HIF-1) Signaling in Therapeutics: Implications for the Treatment of Inflammatory Bowel Disease
Recent Patents on Inflammation & Allergy Drug Discovery Editorial (Thematic Issue: Thyroid Hormones. From Molecular Signaling to Human Disease: An Update)
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Enzymatic Properties and Physiological Roles of Cytosolic 5’-Nucleotidase II.
Current Medicinal Chemistry The Emerging Role of Bcr-Abl-Induced Cystoskeletal Remodeling in Systemic Persistence of Leukemic Stem Cells
Current Drug Delivery Micro-RNA in Disease and Gene Therapy
Current Drug Discovery Technologies microRNAs in Cancer: Lessons from Melanoma
Current Pharmaceutical Design Viral Proteases as Targets for Drug Design
Current Pharmaceutical Design